Difficulty: Medium
Average Score: 68%
Practice
The most appropriate treatment for newly diagnosed bronchial asthma with occasional symptoms:
Correct answer
B
Rationale
In the treatment of newly diagnosed bronchial asthma with occasional symptoms, the most appropriate initial therapy is a low dose inhaled corticosteroid (ICS) (Option B).
The rationale behind choosing a low dose ICS is based on current evidence-based guidelines that recommend ICS as first-line therapy for asthma management. ICS helps reduce airway inflammation, which is a key component in asthma pathophysiology. By using ICS early in treatment, we can achieve better control of symptoms, prevent exacerbations, and improve overall lung function.
Option A, inhaled short-acting B2 agonists, is used for quick relief of acute symptoms but is not recommended as monotherapy for long-term asthma control. Option C, anti-leukotrienes, are an alternative but are generally reserved for cases where ICS are not tolerated or effective. Option D, slow-release theophylline, is not typically recommended as first-line therapy due to its narrow therapeutic window and potential for side effects.
Educationally, it is crucial for healthcare providers to understand the rationale behind selecting appropriate asthma therapies to provide optimal care for pediatric patients. By choosing evidence-based treatments like low dose ICS, healthcare providers can effectively manage asthma symptoms, improve quality of life, and prevent disease progression in pediatric patients.
The rationale behind choosing a low dose ICS is based on current evidence-based guidelines that recommend ICS as first-line therapy for asthma management. ICS helps reduce airway inflammation, which is a key component in asthma pathophysiology. By using ICS early in treatment, we can achieve better control of symptoms, prevent exacerbations, and improve overall lung function.
Option A, inhaled short-acting B2 agonists, is used for quick relief of acute symptoms but is not recommended as monotherapy for long-term asthma control. Option C, anti-leukotrienes, are an alternative but are generally reserved for cases where ICS are not tolerated or effective. Option D, slow-release theophylline, is not typically recommended as first-line therapy due to its narrow therapeutic window and potential for side effects.
Educationally, it is crucial for healthcare providers to understand the rationale behind selecting appropriate asthma therapies to provide optimal care for pediatric patients. By choosing evidence-based treatments like low dose ICS, healthcare providers can effectively manage asthma symptoms, improve quality of life, and prevent disease progression in pediatric patients.